A new study showed that SOCS1 regulation of GM-CSF signaling is dose-dependent. The study, which involved generating a novel ...

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

Jane Street Group LLC bought a new stake in XBiotech Inc. (NASDAQ:XBIT – Free Report) in the 3rd quarter, according to its ...

CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments. "We are very optimistic about the prospects of our ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.

Treatment with risankizumab following inadequate response to secukinumab or ixekizumab was associated with improved disease severity, quality of life, and symptoms among patients with plaque psoriasis ...